Adrienne E. Balitza

Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model

Mark T. Bilodeau, Adrienne E. Balitza, J. M. HOFFMAN et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 81 citations · Full text

Tumor Biology, Medicine, Pharmacotherapy +8

Potent <i>N</i>-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel

Mark T. Bilodeau, Adrienne E. Balitza, Timothy J. Koester et al. · Journal of Medicinal Chemistry · 2004 · 60 citations · Full text

Drug Target, Pharmacotherapy, Molecular Pharmacology +20

Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

Zhicai Wu, Mark E. Fraley, Mark T. Bilodeau et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 42 citations · Full text

Vegf-receptor Kdr, Medicinal Chemistry, Biochemistry +9

2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors

Peter J. Manley, Adrienne E. Balitza, Mark T. Bilodeau et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 28 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Kdr Kinase Inhibitors +5